Showing 941-950 of 1017 results for "".
- Positive 90-Day Results from CONFORM Study: Recros Medicahttps://practicaldermatology.com/news/positive-90-day-results-from-conform-study-recros-medica/2460042/Ninety-day results from the CONFORM study assessing the efficacy, safety, and patient satisfaction of the Rotational Fractional Resection (RFR) procedure for submental contouring are promising. RFR is a novel, proprietary alternative to traditional approaches to treat skin laxity developed by
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2019-aspire-higher-scholarship-program/2459978/Ortho Dermatologics is accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. Students can apply for the Aspire Higher scholarship through April 26, 2
- Senté to Introduce Intensive Bio Complete Creamhttps://practicaldermatology.com/news/sent-to-introduce-intensive-bio-complete-cream/2459927/Senté is expanding their family of skincare products with the upcoming launch of Intensive Bio Complete Cream. Slated to be available on Feb. 11, 2019, the new nighttime cream is an “advanced retinol,” explains Virginia L. Vega, Ph.D., Senté ’s Vice
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Allergan's SkinMedica Tackles Blue Light and More with New LUMIVIVE Systemhttps://practicaldermatology.com/news/skinmedica-tackles-blue-light-and-more-with-new-lumivie-system/2457620/Allergan is launching the SkinMedica LUMIVIVE System, with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's repair process at night for 24-hour protection and revital
- Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2018-aspire-higher-scholarship-recipients/2457658/Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine st
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f